Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reply to Correspondence

Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):e226-e227. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0128

View: 1066 Download: 30

Correspondence

Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):e186-e188. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0079

View: 791 Download: 37 Web of Science: 1 Crossref: 1

Editorial

Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Nahee Hwang, Sungsoon Fang

Clin Mol Hepatol. 2025;31(2):631-634. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0066

View: 1142 Download: 49 Web of Science: 2 Crossref: 2

Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):628-630. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0036

View: 1225 Download: 47 Web of Science: 2 Crossref: 2

Original Article

GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Xiao-Chen Ma, Chen-He Yi, Bao-Rui Tao, Bo Zhang, Yue Ma, Guo Zhang, Rui Zhang, Yan Geng, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):409-425. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0657

View: 2545 Download: 296 Web of Science: 7 Crossref: 7

Letter to the Editor

Functional cure of chronic hepatitis B encounters resmetirom

Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng

Clin Mol Hepatol. 2024;30(3):580-581. Published online April 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0301

View: 2910 Download: 115 Web of Science: 2 Crossref: 2

Original Article

Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy

Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu

Clin Mol Hepatol. 2024;30(3):515-538. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0107

View: 5294 Download: 322 Web of Science: 6 Crossref: 6

Editorial

GLP-1RA may open a new era for MASLD treatment

Ye Feng, Chengfu Xu

Received June 12, 2025 Accepted June 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0628 [Accepted]

View: 38 Download: 5

1 |

Viewed By 12270	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7643	MAFLD: How is it different from NAFLD?
Viewed By 6664	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5928	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 5531	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 355	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 338	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 223	MAFLD: How is it different from NAFLD?
Cited By 114	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 110	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search